<?xml version="1.0" encoding="UTF-8"?>
<p>Carbonic anhydrases (CAs, EC 4.2.1.1) are zinc enzymes which catalyse the reversible interconversion between CO
 <sub>2</sub> and bicarbonate
 <xref rid="CIT0067" ref-type="bibr">
  <sup>67–71</sup>
 </xref>. CO
 <sub>2</sub> is efficiently hydrated through a zinc hydroxide intermediate from the enzyme active site with generation of the weak base bicarbonate and the strong acid H
 <sup>+</sup>. As a consequence, CAs are involved in pH regulation, electrolyte secretion and metabolism, in normal and tumour tissues
 <xref rid="CIT0070" ref-type="bibr">
  <sup>70–72</sup>
 </xref>. Fifteen α-CA isoforms are present in humans, with at least two of tyhem overexporessed in hypoxic tumours (CA IX and XII)
 <xref rid="CIT0067" ref-type="bibr">
  <sup>67</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0071" ref-type="bibr">
  <sup>71</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0072" ref-type="bibr">
  <sup>72</sup>
 </xref>, as a consequence of the hypoxia inducible factor (HIF-1α) transcription factor cascade activation
 <xref rid="CIT0067" ref-type="bibr">
  <sup>67</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0070" ref-type="bibr">
  <sup>70</sup>
 </xref>. CAs are efficiently inhibited by a range of compounds, such as the sulphonamides and their isosteres
 <xref rid="CIT0073" ref-type="bibr">
  <sup>73–76</sup>
 </xref>, and inorganic anions
 <xref rid="CIT0077" ref-type="bibr">
  <sup>77</sup>
 </xref>, which constitute the main zinc-binding CA inhibitor (CAI) classes
 <xref rid="CIT0067" ref-type="bibr">
  <sup>67</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0076" ref-type="bibr">
  <sup>76</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0077" ref-type="bibr">
  <sup>77</sup>
 </xref>. Some of the CAIs belonging to the sulphonamide
 <xref rid="CIT0078" ref-type="bibr">
  <sup>78</sup>
 </xref>, sulfocoumarin
 <xref rid="CIT0079" ref-type="bibr">
  <sup>79</sup>
 </xref>, saccharin
 <xref rid="CIT0080" ref-type="bibr">
  <sup>80</sup>
 </xref> or other structurally related chemotypes
 <xref rid="CIT0081" ref-type="bibr">
  <sup>81</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0082" ref-type="bibr">
  <sup>82</sup>
 </xref>, were shown to possess significant antitumor effects, with one such derivative (
 <bold>SLC-0111</bold>) in Phase I/IIb clinical trials for the management of hypoxic metastatic tumours
 <xref rid="CIT0078" ref-type="bibr">
  <sup>78</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0083" ref-type="bibr">
  <sup>83</sup>
 </xref>. Indeed, by inhibiting the tumour-associated isoforms CA IX and XII, such CAIs interfere with the pH regulation and metabolism of tumours, leading to the inhibition of growth of the primary tumour, metastases and reducing the population of cancer stem cells
 <xref rid="CIT0078" ref-type="bibr">
  <sup>78</sup>
 </xref>. As a consequence, many CAIs belonging to various classes are nowadays investigated for their antitumor/antimetastatic effects, including many BTA derivatives (
 <xref ref-type="fig" rid="F0043">Figure 43</xref>)
 <xref rid="CIT0084" ref-type="bibr">
  <sup>84–91</sup>
 </xref>.
</p>
